DB18197ExperimentalProtein Based Therapies
ST-003 is a novel galanin receptor inhibitor being investigated for the treatment of primary sclerosing cholangitis.
- Mechanism
- Curator reviewed
Pharmacologically active on Galanin receptor type 2 and Galanin receptor type 1
- Also known as
- Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu- Gly-Pro-Pro-Pro-Ala-Leu-Ala-Leu-Ala-NH2 · L-Alaninamide, glycyl-L-tryptophyl-L-threonyl-L-leucyl-L-asparaginyl-L-seryl-L-alanylglycyl-L-tyrosyl-L-leucyl-L-leucylglycyl-L-prolyl-L-prolyl-L-prolyl-L-alanyl-L-leucyl-L-alanyl-L-leucyl-
- Code names
- M-40 · ST-003
Resolves to
Compound
Targets
What you can answer from here — as of July 09, 2026
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with ST-003, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account